Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][53]. Core Viewpoints - The report emphasizes the strong logic behind the innovative drug industry, suggesting that the stock prices have adjusted sufficiently, making current investments relatively cost-effective. It recommends focusing on stocks with high or certain returns, particularly those expected to perform well in Q1 [5][42]. - The report highlights the rapid growth of balloon-expandable valves (BEV) in TAVR procedures, with a projected increase in the number of procedures in China, reaching over 18,000 by 2025, representing an 8.1% year-on-year growth. The proportion of BEV usage is expected to rise significantly [8][16]. - The report outlines a dual investment framework focusing on "technology innovation leadership" and "performance/valuation recovery" for the year [23][43]. Summary by Sections 1. TAVR Procedure Growth - The number of TAVR procedures in mainland China is expected to exceed 18,000 by 2025, with a year-on-year growth of 8.1%. The proportion of balloon-expandable valves is projected to increase from 7.5% in 2024 to 13% in 2025 [8][16]. 2. Industry Performance Analysis - From March 2 to March 6, the pharmaceutical index fell by 2.78%, underperforming the CSI 300 index by 1.71%. Despite this, innovative drugs showed a significant rebound, with stocks like Yahu Medicine rising over 38% [5][23]. - The report lists several stocks to watch, including innovative drug companies and those with stable growth or potential for performance reversal [5][42]. 3. Investment Recommendations - The report suggests focusing on innovative drugs, AI medical technology, and surgical robots as key areas for investment in 2026. Specific companies highlighted include Heng Rui Medicine, Xin Li Tai, and Bai Ren Medical [5][42][45]. - It also emphasizes the importance of the aging population and outpatient consumption as growth drivers, recommending companies like Kun Yao Group and Yu Yao Medical [45]. 4. Market Trends and Valuation - The overall PE valuation for the pharmaceutical sector is 36.18x, indicating that the sector remains at a relatively low historical valuation. The report notes that various sub-sectors have differing valuation levels, with some being relatively high [31][42].

Summary of Conference Call on Interventional Valves Industry Overview - The heart valve market is experiencing a slowdown in growth, expected to maintain around 20% growth due to market maturity, medical cost control, and price competition within the industry [1][2] - Major brands in the market include Peijia, Qiming, Jintong, and Jianshi, with Jianshi focusing on cash valves [1] - The expected implantation volume for interventional valves in the first half of 2025 is approximately 21,000 cases, with a growth rate of about 20% [2] Key Insights - The market has transitioned from a high-growth phase (40-50% from 2019 to 2022) to a more stable growth phase, with current growth seen as satisfactory [2] - Factors contributing to the slowdown include the market reaching its initial explosive growth phase, economic conditions leading to medical cost control, and increased price competition among manufacturers [2] - The expected price range for heart valves post-collective procurement is projected to drop to between 120,000 to 150,000 yuan, which is about 60-70% of the original factory price [1][8] Pricing and Subsidies - The lowest market price for Lepu's new balloon-expandable valve is 100,000 yuan, while the listed price in Guangzhou is around 158,000 to 160,000 yuan, serving as a reference for price reductions in other provinces [1][7] - Companies like Qiming, Peijia, and Xintong are providing subsidies ranging from 30,000 to 50,000 yuan in central and western regions, although these amounts have decreased compared to previous years [5][6] Market Dynamics - The current market structure is not expected to change significantly in the short term. New entrants must either offer lower prices to gain access or enhance clinical services to improve hospital recognition [9] - The collective procurement policy is anticipated to have a moderate impact on pricing, with potential participation from multiple provinces [4] Product Performance - The implantation volume for Jianshi's cash valves in the first half of 2025 is expected to be around 1,600 cases, while new entrants like Lepu and Shanghai Niupai have seen very low implantation volumes [3] - Self-expanding valves are more widely used, accounting for 95% of implantation volumes, while balloon-expandable valves are noted for their precision and lower complication rates [11] Future Outlook - The domestic electrophysiology market has seen a slowdown in growth, with an expected completion of 550,000 electrophysiology procedures in 2025, but the growth rate is expected to decline further post-2023 due to the saturation of suitable patient populations [27][29] - The development of one-stop atrial fibrillation ablation combined with left atrial appendage closure procedures is promising, although it faces challenges due to payment system limitations [30] Conclusion - The heart valve market is stabilizing with moderate growth expectations, influenced by pricing strategies, competitive dynamics, and regulatory changes. The focus for companies will be on maintaining market share through innovation and effective pricing strategies while navigating the challenges posed by collective procurement policies and market saturation.